What's in HEM Pharma Inc.'s pipeline?

HEM Pharma Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with HEM Pharma Inc.'s portfolio?

Top competitors by shared drug class: Chang Gung Memorial Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hem-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

HEM Pharma Inc. — Portfolio Competitive Intelligence Brief

HEM Pharma Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lactobacillus Fermentum	Lactobacillus Fermentum	marketed	Live biotherapeutic / Probiotic		Gastroenterology / Immunology

Therapeutic area mix

Gastroenterology / Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Chang Gung Memorial Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for HEM Pharma Inc.:

Cite this brief

Drug Landscape (2026). HEM Pharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hem-pharma-inc. Accessed 2026-05-15.